Teligent Inc. (NASDAQ:TLGT) shares traded down 3.5% during trading on Wednesday . The company traded as low as $7.97 and last traded at $8.02, with a volume of 88,926 shares. The stock had previously closed at $8.31.

Several analysts have recently issued reports on TLGT shares. Zacks Investment Research cut Teligent from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 30th. Oppenheimer Holdings Inc. reaffirmed a “hold” rating on shares of Teligent in a report on Tuesday, April 26th. TheStreet raised Teligent from a “sell” rating to a “hold” rating in a report on Thursday, June 23rd. JMP Securities started coverage on Teligent in a report on Wednesday, June 29th. They set a “hold” rating on the stock. Finally, Raymond James Financial Inc. started coverage on Teligent in a report on Wednesday, June 22nd. They set a “strong-buy” rating and a $11.00 price objective on the stock. Four analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. Teligent presently has an average rating of “Buy” and a consensus target price of $9.42.

The firm’s 50-day moving average is $8.06 and its 200-day moving average is $6.33. The company’s market cap is $423.17 million.

Teligent (NASDAQ:TLGT) last posted its earnings results on Thursday, July 28th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.04. During the same period last year, the business earned ($0.05) earnings per share. The company had revenue of $17.14 million for the quarter, compared to analyst estimates of $16.03 million. The firm’s revenue was up 92.8% on a year-over-year basis. On average, analysts forecast that Teligent Inc. will post $0.05 earnings per share for the current year.

Teligent, Inc, formerly IGI Laboratories, Inc, is a specialty generic pharmaceutical company. The Company markets and sells generic injectable pharmaceutical products under its own label in the United States and Canada. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.